Online inquiry

IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5462MR)

This product GTTS-WQ5462MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets tcdB gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_003434531.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299394
UniProt ID P18177
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5462MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ320MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ12214MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ8851MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ7619MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ6790MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ4394MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ14392MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ5398MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW